BioMarin Pharmaceutical Inc. Files 8-K

TL;DR

BMRN filed an 8-K on Oct 7, 2025, reporting on financial condition. No specifics yet.

AI Summary

On October 7, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition. No specific financial figures or operational details were disclosed in the provided text, but the filing indicates a standard reporting event.

Why It Matters

This filing indicates BioMarin Pharmaceutical Inc. is providing an update on its financial condition and operational results to the SEC, which is important for investors to monitor company performance.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting on financial condition and results of operations, without immediate material new information disclosed in the provided text.

Key Players & Entities

• BIOMARIN PHARMACEUTICAL INC (company) — Registrant
• October 7, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 68-0397820 (identifier) — I.R.S. Employer Identification No.
• 770 Lindaro Street San Rafael California 94901 (address) — Principal Executive Offices
• 415-506-6700 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market In
• $221 million — acquired IPR&D charges of approximately $221 million on a pre-tax basis, representing a char
• $1.10 — representing a charge of approximately $1.10 to both GAAP Diluted earnings per share

Filing Documents

• bmrn-20251007.htm (8-K) — 28KB
• 0001048477-25-000101.txt ( ) — 143KB
• bmrn-20251007.xsd (EX-101.SCH) — 2KB
• bmrn-20251007_lab.xml (EX-101.LAB) — 21KB
• bmrn-20251007_pre.xml (EX-101.PRE) — 12KB
• bmrn-20251007_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. E stimated Third Quarter 2025 Acquired In-Process Research and Development (IPR&D) Charges In connection with its previously announced acquisition of Inozyme Pharma, Inc. on July 1, 2025, BioMarin Pharmaceutical Inc. (BioMarin) expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles (GAAP) and its Non-GAAP financial results for the third quarter of 2025 will include acquired IPR&D charges of approximately $221 million on a pre-tax basis, representing a charge of approximately $1.10 to both GAAP Diluted earnings per share (EPS) and Non-GAAP Diluted EPS. BioMarin's results for the quarter ended September 30, 2025, have not been finalized and are subject to BioMarin's financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. The preliminary, unaudited financial information in this Current Report on Form 8-K (this Report) does not present all information necessary for a complete understanding of BioMarin's results for the quarter ended September 30, 2025, and should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. As previously disclosed, while acquired IPR&D charges may be incurred upon execution of acquisitions, collaborations, licensing agreements, and other business development transactions, BioMarin does not forecast acquired IPR&D charges at the time of execution of such agreements due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period. The information in this Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor sh

Forward-Looking Statements

Forward-Looking Statements This Report contains forward-looking statements about, among other things, BioMarin's anticipated acquired IPR&D charges for the quarter ended September 30, 2025, and the related impact to BioMarin's GAAP Diluted EPS and Non-GAAP Diluted EPS. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, additional procedures BioMarin will undertake to finalize its results for the period that could result in changes to BioMarin's preliminary estimates described herein and those detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise. Non-GAAP Information This Report references Non-GAAP Diluted EPS, which is a financial measure that is not calculated in accordance with GAAP. Non-GAAP Diluted EPS is defined by BioMarin as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by BioMarin as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under BioMarin's equity plans and convertible debt in periods when they are dilutive under Non-GAAP. Non-GAAP Income is defined by BioMarin as GAAP Net Income excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specif

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: October 7, 2025 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR